Albuterol Sulfate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Albuterol Sulfate: Drug Repurposing Evaluation — Insufficient Data for Prediction
One-Sentence Summary
Albuterol Sulfate is a well-known short-acting beta-2 adrenergic agonist (SABA) commonly used as a bronchodilator for conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, the current Evidence Pack contains no TxGNN-predicted new indications, no approved indication records in the Singapore registry, and no mechanism of action data — making a full repurposing evaluation impossible at this stage. This report documents the data gaps and recommends remediation steps before any repurposing assessment can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no Singapore registration records) |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — prediction pipeline did not produce output |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN predicted indications were returned for Albuterol Sulfate in this Evidence Pack (predicted_indications: []). Without a prediction target, a mechanism-to-indication bridging analysis cannot be constructed.
Additionally, detailed mechanism of action data was not retrieved from DrugBank (DrugBank ID is null despite a successful query log entry). Without MOA data and a predicted disease target, the core logic of repurposing reasoning — "why would this drug's mechanism apply to a new indication?" — cannot be supported.
This section will be populated once the prediction pipeline is re-run with a valid DrugBank mapping and at least one predicted indication is returned.
Clinical Trial Evidence
Currently no related clinical trials registered for a repurposing indication.
(No predicted indication target exists from which to derive a trial search context.)
Literature Evidence
Currently no related literature available.
(No predicted indication target exists from which to derive a literature search context.)
Singapore Market Information
Albuterol Sulfate has no registered products in the Singapore Health Sciences Authority (HSA) database as of the data cutoff (2026-04-19).
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No records found |
Note: Albuterol (also known internationally as Salbutamol) is widely registered in many markets under the INN "Salbutamol." It is possible that Singapore HSA records exist under the alternative INN. A cross-query using "Salbutamol" is recommended before concluding non-registration.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for Albuterol Sulfate is critically incomplete — no predicted indications, no DrugBank ID linkage, no Singapore registration records, and no safety data are available. There is insufficient information to evaluate any repurposing hypothesis at this time.
To proceed, the following is needed:
- Re-run TxGNN prediction pipeline with a confirmed DrugBank ID for Albuterol Sulfate (DrugBank: DB01001 for Salbutamol) to obtain predicted indications
- Cross-check Singapore HSA registry using the alternative INN "Salbutamol" to determine true market status
- Retrieve MOA from DrugBank API using DB01001 to populate the mechanism of action field
- Download and parse the product insert (PIL/SmPC) from HSA or EMA to populate safety warnings and contraindications
- Resubmit Evidence Pack once the above data gaps (DG001, DG002) are resolved, then re-generate this report against the enriched pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.